Why the study?
Does Co-enzyme Q10 prevent doxorubicin-induced cardiomyopathy in a rat model?
Population
Four-week-old SD rats
Comparison
Co-enzyme Q10 added to doxorubicin challenge vs Doxorubicin alone, Q10 alone, and control
Design
Preclinical
Follow-up
3 weeks
Authors
Loading...
Hypothesis-generating in rats; leaves open any clinical role for Q10 pending human trials.
Does Co-enzyme Q10 prevent doxorubicin-induced cardiomyopathy in a rat model?
Co-enzyme Q10 demonstrates potential in preventing doxorubicin-induced cardiomyopathy and fibrosis in a preclinical rat model.
Chen et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: